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each condition were performed on 4 test/control pairs for both
cB and cAC.
To verify that the cB removed a significant amount of the DS,
specimens were cut into 14 sections, 7 in a top half layer and
7 in a bottom half layer, and Western blot analysis for the
decorin protein performed on each section. For comparison, cAC
specimens were cut in a similar fashion and total proteoglycans
assayed with the DMB assay.
Results: cB had no detectable effect on rapid modulus, equilib-
rium modulus, or relaxation function in indentation. Conversely,
cAC caused reduction in equilibrium modulus and relaxation
function, consistent with published work of others. Approximately
one-half of the DS was removed from the top layer. Assay of the
cAC specimens for total proteoglycan showed similar digestion
patterns, suggesting that the two enzymes acted similarly.
Conclusions: Removal of DS from the cartilage did not affect
the viscoelastic properties of the cartilage, indicating that decorin
is not a structural molecule in cartilage in indentation.
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Purpose: There is growing recognition that environmental fac-
tors may play a significant role in determining the health of
musculoskeletal tissues, including cartilage. Many of the cellu-
lar mechanisms that contribute to cartilage catabolism such as
oxidative stress, altered growth factor signaling, matrix mineral-
ization and activation of metaloproteinases can be initiated by
heavy metal toxicants. The aim of this study was to determine
if heavy metal toxicants activate chondrocyte mitogen-activated
protein kinases (MAPKs) that can then lead to altered cartilage
homeostasis.
Methods: Chondrocytes were enzymatically isolated from com-
mercially obtained 4-6 month-old porcine knee joints (approved
by the UNC IACUC) by sequential digestion in pronase and
collagenase, and grown in high-density monolayer culture (105
cells/cm2). Cultures were serum-starved overnight and subse-
quently treated with organic methylmercury (MeHg), inorganic
mercuric chloride (HgCl2), or lead acetate (PbAc), for up to 60
minutes at varying concentrations prior to cell extraction with
ice-cold lysis buffer. Additional cultured were treated with IL-1.
Activation of MAPKs was determined by western blotting using
phosphorylation-specific polyclonal antibodies.
Results: MeHg and caused transient activation of JNK at con-
centrations as low as 1uM, though the degree of activation by
MeHg was lower than by IL-1. Maximal activation occured at
10 minutes, returning to baseline levels within 30 minutes. p38
MAPK was activated by IL-1, but not MeHg or HgCl2, within this
time frame. HgCl2 and PbAc treatments also caused transient
activation of JNK, with maximal activation at 10 minutes.
Conclusions: Environmental toxicants are recognized as con-
tributing factors in many chronic human diseases. This study
demonstrates that environmental heavy metals activate JNK in
articular chondrocytes and suggests that metals may influence
the rate or severity of osteoarthritis through modulation of intra-
cellular signaling pathways.
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Purpose: Pomegranate fruit (Punica granatum L) is revered
through the ages for its medicinal properties. Pomegranate fruit
(PF) or its extract (PFE) is widely used in Asian and Mediter-
ranean cultures for the treatment of inflammation, for pain in
arthritis and other diseases. Osteoarthritis (OA) is the most
common musculoskeletal disease among the aging population.
Pro-inflammatory cytokine IL-1β plays a dominant role in OA
pathogenesis which is characterized by degeneration of articular
cartilage of the joints in hands, knees, spine and hips. We have
evaluated the effects of a standardized PFE preparation on hu-
man OA cartilage and OA chondrocytes treated with IL-1β with a
view to determining whether consumption of PF or PFE can be
useful in preventing joint cartilage degradation in OA.
Methods: Human cartilage and synovial fluid (SF) were obtained
at the time of hip arthroplasty. Cartilage explants were prepared
by standard methods and chondrocytes were liberated by en-
zymatic dissociation from femoral heads. Cartilage explants or
chondrocytes were treated with IL-1β (5 ng/ml) or IL-1β and
PFE (10 - 200 μg/ml) using previously described methods. The
effect of PFE on IL-1β-induced apoptosis in chondrocytes was
determined by viability assays and Western blotting. Substrate-
embedded enzymography and/or collagen degradation assays
were used to characterize the MMP activity in conditioned me-
dia and SF. Western immunoblotting and immunoprecipitation
was used to confirm the presence and/or interaction of specific
proteins in the SF and conditioned media. Quantitative RT-PCR
was employed to quantify MMP mRNA expression levels. Human
chondrocyte nucleofection with reporter constructs was used to
analyze the effect of PFE on IL-1β-induced gene promoter activ-
ity. Cartilage explants were stained with Safranin-O/Fast Green.
Matrix proteoglycan and collagen degradation was determined
in culture supernatant using metachromatic assays. The results
were analyzed using the Student-t test where p<0.05 was con-
sidered significant.
Results: PFE at the concentrations used was found to be non-
toxic and remarkably effective in inhibiting IL-1β-induced human
chondrocyte apoptosis. PFE also blocked the gelatinolytic ac-
tivities of recombinant human MMPs as well as MMP activity
recovered from SF of OA patients. Quantitative zymography
also showed that in IL-1β-stimulated human chondrocytes cul-
tures pretreated with PFE the substrate degrading activity of
MMP-9 and MMP-13 was significantly lower (p <0.05). Western
immunoblotting showed that IL-1β-induced protein expression
of MMP-9 and MMP-13 was inhibited when human chondro-
cytes were pre-treated with PFE. Quantitative RT-PCR showed
that PFE blocked MMP-9 and MMP-13 mRNA expression. Fur-
thermore, PFE inhibited IL-1β-induced MMP-9 and -13 gene
promoter activity (p <0.005) in transfected human chondrocytes
indicating that PFE was acting at the level of transcription.
Histochemical and biochemical analysis of human cartilage ex-
plants showed that the proteoglycan and Type-II collagen content
loss was significantly less (p <0.05) in cartilage explants when
PFE was present during IL-1β stimulation or when activated re-
combinant MMPs were exogenously added to explant cultures
pretreated with PFE. Chondrocytes cultured in the presence of
PFE also showed increased proteoglycan and collagen synthe-
sis. PFE also blocked the IL-1β-induced loss and inhibition of
matrix synthesis.
Conclusions: Our results indicated that PFE blocked the IL-1β-
induced human cartilage degradation and MMP-9 and MMP-13
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gene expression and activity in vitro. Oral consumption of PFE or
active compounds derived from PFE may be protective against
cartilage degradation in OA.
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Purpose: Miniperl is an alternative spliced form of perlecan,
a proteoglycan that has both structural and functional roles in
a variety of tissues including cartilage. Its sequence shares
the beginning part with perlecan domain I with exons 4 and
5 spliced out resulting in a frame shift and termination shortly
after. The resulting protein shares a portion identical to perlecan
and a unique amino acid sequence (AF479675). This study
addresses the protein characteristics of miniperl and provides a
tool to begin to study its function in both chondrogenesis and
in other tissues. Further characterization of this novel chimeric
protein will bring new information as to the role(s) that this
gene may have in development, normal cell and tissue function,
and disease. We used a system that takes the advantages
of BM40 signal peptide and GFP for protein monitoring. The
tripartite system contained coding sequences for BM40 signal
peptide, miniperl, and IRES-EGFP in two reading frames under
the control of CMV promoter. Miniperl has been characterized by
Western blot and immunoprecipitation with perlecan and miniperl
antibodies. Unlike perlecan, in labeling studies performed thus
far using osteoarthritic chondrocytes, miniperl does not have an
associated gylcosaminoglycan chain.
Methods: Several steps were performed to include the desired
components and prepare the miniperl sequence for insertion into
the dual expression vector (with GFP). The miniperl transcript
was first inserted into vector pcDNA6/V5-His, then subcloned
into the 3’-end of the BM40 signal peptide gene sequence
in another vector pCEP-Pu/BMs.The BM40-miniperl-V5-His tag
gene sequences were then cloned into pFM2.2 vector. The vector
is designated as pFM-BM40-miniperl-V5-His. It was grown in E.
coli GC5 cells, prepared with a Qiagen endo-free DNA prep kit.
Human chondrocytes were isolated from osteoarthritis patients’
cartilage obtained from NDRI using IRB-approved protocols.
Chondrocytes were isolated by routine procedures using colla-
genase followed by culture in DMEM and grown in 5% CO2
at 37°C. Chondrocytes were cultured in suspension to maintain
their cartilage phenotype and transferred for 24 hr to adherent
conditions for transfection using the nucleofector kit (Amaxa Inc.).
Metabolic labeling and immunoprecipitation were performed with
35S-labeled sodium sulfate and cysteine-methionine. Rabbit poly-
clonal anti-miniperl antibodies were prepared to the unique pro-
tein sequence.
Results: The mammalian expression vector pFM-BM40-
miniperl-V5-His was successfully constructed and the correct
sequence confirmed by DNA sequencing. The unique properties
of this vector allow separate expression of the miniperl and GFP
permitting expression monitoring and cell analysis and sorting.
Human chondrocytes were transfected with cells in suspension
after a 24-hour period of adherence using the Amaxa nucleofec-
tor kit. Cell culture medium were harvested and analyzed.
Protein of 25-35 kDa is identified on Western blots using per-
lecan, anti-perlecan domain I-specific, and anti-miniperl antibod-
ies.
Immunoprecipitation with perlecan and miniperl specific antibod-
ies indicates the high level expression of miniperl and met/cys
labeled bands do not appear labeled with 35S-NaSO4 indicating
the lack of GAG.
Conclusions: In this study we generated an efficient construct
for the expression of miniperl in human chondrocytes. The tripar-
tite system of BM40 signal peptide, miniperl, and IRES-EGFP in
two reading frames under the control of CMV promoter proved
the high-level expression and easy detection. Unlike perlecan,
labeled miniperl does not have an associated gylcosaminoglycan
chain in osteoarthritic chondrocytes and additional studies will
demonstrate if this is consistent in normal chondrocytes and in
other tissues.
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Purpose: Recent studies showed a beneficial effect of COX-2
inhibition on proteoglycan turnover of both IL-1β/TNFα induced
cartilage damage as well as of osteoarthritic cartilage. Although
proteoglycan release and content normalized, proteoglycan syn-
thesis was only partially influenced. Because prostaglandin-E2
(PGE2) is the main product formed by COX-2, this suggests
prostaglandin-E2 to play an important role in disturbance a carti-
lage proteoglycan release but not synthesis, which was subject
of the present study.
Methods: Human healthy cartilage, alone or in the presence
of IL-1β+TNFα (200+800 pg/ml, resp.), was cultured for 7 days
with or without prostaglandin-E2 (3 up to 500 pg/ml) or the
selective COX-2 inhibitor (celecoxib 10 μM). Changes in cartilage
matrix proteoglycan turnover, prostaglandin-E2 and NO were
determined
Results: Proteoglycan synthesis and release of the cartilage
tissue were not affected by prostaglandin-E2 alone. Addition
of IL-1β+TNFα to the healthy cartilage resulted in inhibition
of proteoglycan synthesis and increased proteoglycan release
(p<0.05). When in combination with IL-1β+TNFα, prostaglandin-
E2 (200 pg/ml) was added proteoglycan release further increased
(p<0.05), but, proteoglycan synthesis was not further influenced.
Addition of a selective COX-2 inhibitor could reverse the ad-
verse characteristics of the combination of IL-1β/TNFα treated
normal cartilage. The effect was very clear for release, up to
almost complete normalization, whereas for synthesis the effect
was marginal. In these experiments, celecoxib was also able
to normalize the enhanced prostaglandin-E2-levels, whereas en-
hanced NO-levels remained elevated in the presence of cele-
coxib. Prostaglandin-E2 levels correlated significantly with pro-
teoglycan release (corr. coefficient: 0.499; p<0.000), whereas
NO levels correlated significantly with proteoglycan synthesis
(corr. coefficient: -0.626; p<0.000).
Conclusions: The present results suggest involvement of
prostaglandin-E2 in enhanced cartilage proteoglycan release,
although healthy cartilage has to be sensitized by IL-1β/TNFα.
IL-1β/TNFα induced NO seems to be more involved in inhibition
of proteoglycan synthesis, independent of prostaglandin-E2 and
with that insensitive to regulation by (selective) COX-2 inhibitors.
